Biophotonic Nanoparticle-enabled Laser Blood Test for Early Detection of Pancreatic Cancer

LASERBLOOD is based on a biophotonic technology that can be used to predict the development of Pancreatic Ductal Adenocarcinoma (PDAC) in particular categories of subjects at risk (e.g. persons with diabetes, obese people, patients with Intraductal Papillary Mucinous Neoplasm \[IPMN\] or other cystic diseases of the pancreas, etc.) and at the same time offer the possibility of verifying the real effectiveness of the treatments to which affected patients are subjected.

NCT Number	NCT07659639
Lead Sponsor	Fondazione Policlinico Universitario Campus Bio-Medico
Conditions	Diabetes, IPMN, Pancreatic, PDAC - Pancreatic Ductal Adenocarcinoma
Enrollment	400 participants
Start Date	2025-09-01
Primary Completion	2029-08 (estimated)
Study Completion	2029-08 (estimated)
Updated on ClinicalTrials.gov	2026-06-22